Switch theme
Sign up to access all valuation multiples
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.
2000
19
LTM Revenue n/a
LTM EBITDA -$28.4M
$190M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
DiaMedica has a last 12-month revenue of n/a and a last 12-month EBITDA of -$28.4M.
In the most recent fiscal year, DiaMedica achieved revenue of n/a and an EBITDA of -$21.2M.
DiaMedica expects next 12-month revenue of XXX and NTM EBITDA of XXX
See DiaMedica valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$21.2M | -$26.1M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$13.6M | -$13.7M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of March 12, 2025, DiaMedica's stock price is $6.
DiaMedica has current market cap of $240M, and EV of $190M.
See DiaMedica trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $190M | $240M | XXX | XXX | XXX | XXX | $-0.63 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of March 12, 2025, DiaMedica has market cap of $240M and EV of $190M.
DiaMedica's trades at n/a LTM EV/Revenue multiple, and -6.7x LTM EBITDA.
Analysts estimate DiaMedica's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for DiaMedica and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $190M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -7.3x | XXX | XXX | XXX |
| P/E | -10.0x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -8.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpDiaMedica's NTM/LTM revenue growth is n/a
DiaMedica's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.1M for the same period.
Over next 12 months, DiaMedica's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate DiaMedica's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for DiaMedica and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 23% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
DiaMedica acquired XXX companies to date.
Last acquisition by DiaMedica was XXXXXXXX, XXXXX XXXXX XXXXXX . DiaMedica acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was DiaMedica founded? | DiaMedica was founded in 2000. |
| Where is DiaMedica headquartered? | DiaMedica is headquartered in United States of America. |
| How many employees does DiaMedica have? | As of today, DiaMedica has 19 employees. |
| Who is the CEO of DiaMedica? | DiaMedica's CEO is Mr. Rick Pauls. |
| Is DiaMedica publicy listed? | Yes, DiaMedica is a public company listed on NAS. |
| What is the stock symbol of DiaMedica? | DiaMedica trades under DMAC ticker. |
| When did DiaMedica go public? | DiaMedica went public in 2007. |
| Who are competitors of DiaMedica? | Similar companies to DiaMedica include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of DiaMedica? | DiaMedica's current market cap is $240M |
| What is the current EBITDA of DiaMedica? | DiaMedica's last 12-month EBITDA is -$28.4M. |
| What is the current EV/EBITDA multiple of DiaMedica? | Current EBITDA multiple of DiaMedica is -6.7x. |
| Is DiaMedica profitable? | Yes, DiaMedica is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
